-
1 day ago | 
biopharminternational.com | Feliza Mirasol
On April 23, 2025, VERAXA Biotech (VERAXA), a Switzerland-based biotech company specializing in designing novel cancer therapies, announced that it has entered into a definitive agreement with Voyager Acquisition, a US-headquartered special purpose acquisition company focused on the healthcare sector, to create a combined business.
-
6 days ago | 
biopharminternational.com | Feliza Mirasol
A research team from Tokyo University of Science (TUS) explained in March 2025 that it is exploring ways to improve the delivery of antisense oligonucleotides (ASOs), a class of gene-targeting drugs, to the brain and other organs (1). Led by Professor Makiya Nishikawa, the team is following sustainable development goals (SDGs) put forth by the United Nations (2), particularly improving good health and well-being (SDG 3) and promoting industry, innovation, and infrastructure (SDG 9).
-
6 days ago | 
biopharminternational.com | Feliza Mirasol
On Apr 15, 2025, US-based Cellino, a biotechnology company specializing in autonomous biomanufacturing for personalized regenerative medicine, announced a strategic collaboration with South Korea-based Karis Bio, a cell therapy biotech. Through the partnership, the companies aim to industrialize a clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy, the world’s first, according to the companies, for treating peripheral artery disease and coronary artery disease.
-
1 week ago | 
biopharminternational.com | Feliza Mirasol
Teva Pharmaceuticals, a United States-based affiliate of Teva Pharmaceutical Industries, and Samsung Bioepis launched eculizumab-aagh (under the brand name EPYSQLI), a biosimilar referencing eculizumab (brand name Soliris), in the US in April 2025.
-
2 weeks ago | 
biopharminternational.com | Feliza Mirasol
UK-based Entos Pharmaceuticals (Entos), a clinical-stage genetic medicines company, has entered into a research collaboration with Norway-based Circio Holding, a biotechnology company specializing in circular RNA technology for next-generation nucleic acid medicines, under which Entos will develop and validate proteolipid vehicle (PLV) formulations of Circio´s circular RNA expression vectors (circVec) DNA vectors.
-
2 weeks ago | 
biopharminternational.com | Feliza Mirasol
Enosium Life Science, a France-based company specializing in scientific services for the healthcare industry, has acquired Rweality, a consulting firm also based in France that specializes in the evaluation of public policies, technologies, and healthcare practices, in a strategic transaction that is a key step in Enosium Life Science’s growth in building a multi-specialist group across the whole value chain of health products—from clinical development to scientific communication.
-
2 weeks ago | 
biopharminternational.com | Feliza Mirasol
The European Medicines Agency (EMA) announced on April 1, 2025 that it is exploring ways to improve the development and evaluation of biosimilar therapies that will still uphold strict European Union (EU) safety standards and has published a proposal, a draft reflection paper (1,2). The agency has to date more than two decades of experience in evaluating biosimilars (3) and anticipates that this new proposed approach will improve access to biosimilars for patients in the EU.
-
2 weeks ago | 
biopharminternational.com | Feliza Mirasol
April 6, 2025BioPharm InternationalBioPharm International April 2025Pages: 11–13Wider adoption of single-use technologies and systems is aligning with sustainability goals for the industry. Single-use technologies (SUTs) and single-use systems (SUS) have become well established in biomanufacturing, but with growing focus on sustainability in the industry, the importance of how and where these systems contribute to sustainability efforts needs discussion.
-
2 weeks ago | 
biopharminternational.com | Patrick Lavery |Feliza Mirasol
Editor's note: this interview was originally published on PharmTech.com. Michael Franco, global sales director at PSG Biotech, sat down with the PharmTech Group at INTERPHEX 2025 and discussed how recent advancements in pharmaceutical flow sensor technology primarily focus on improving measurement accuracy as drug production becomes more expensive and precise. He points out a key development, which is the enhancement of Coriolis single-use flow meters.
-
2 weeks ago | 
biopharminternational.com | Feliza Mirasol
Maintaining a sterile cleanroom environment and stringent cleanroom protocols in biopharmaceutical manufacturing are critical to ensure optimal product quality and, ultimately, patient safety. With the shift toward personalized medicines, new generation therapies, such as messenger RNA (mRNA), cell and gene therapies (CGTs), antibody-drug conjugates, and modern vaccines, are presenting sterility challenges.
